🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 1 hora
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/12/2020 65,18 65,54 63,85 64,13 -1,41% 2,59% 369.800
24/12/2020 66,40 66,51 64,89 65,05 -0,75% 2,44% 78.500
23/12/2020 65,89 65,91 63,94 65,54 -0,49% 3,00% 283.800
22/12/2020 65,01 67,67 64,37 65,86 +1,18% 5,08% 379.000
21/12/2020 66,31 67,00 64,60 65,09 -3,77% 3,63% 676.800
18/12/2020 65,82 67,91 65,52 67,64 +3,52% 3,63% 1.194.000
17/12/2020 65,00 65,79 64,22 65,34 +0,94% 2,41% 433.900
16/12/2020 66,25 66,93 64,27 64,73 -2,47% 4,01% 369.600
15/12/2020 66,42 67,22 65,32 66,37 +0,55% 2,86% 286.200
14/12/2020 65,97 68,81 65,36 66,01 +1,59% 5,23% 596.300
11/12/2020 63,30 65,55 62,39 64,98 +1,87% 4,99% 480.900
10/12/2020 61,56 64,61 61,56 63,79 +2,90% 4,95% 473.800
09/12/2020 64,41 64,76 61,37 61,99 -3,06% 5,26% 404.500
08/12/2020 59,48 64,09 59,48 63,95 +8,17% 7,75% 505.300
07/12/2020 65,50 66,51 59,10 59,12 -10,03% 11,31% 1.010.600
04/12/2020 64,75 66,00 63,18 65,71 +2,43% 4,36% 400.200
03/12/2020 64,15 64,67 63,41 64,15 +0,45% 1,96% 579.900
02/12/2020 62,76 64,33 61,10 63,86 +1,70% 5,15% 331.900
01/12/2020 63,07 64,33 61,98 62,79 +0,35% 3,72% 1.054.700
30/11/2020 62,35 63,13 59,68 62,57 -2,22% 5,53% 757.000
27/11/2020 64,00 64,61 63,28 63,99 +0,72% 2,08% 245.500
25/11/2020 63,49 64,62 63,22 63,53 +0,60% 2,21% 319.000
24/11/2020 62,84 63,88 62,00 63,15 +1,46% 2,99% 485.600
23/11/2020 63,71 64,00 62,00 62,24 -1,41% 3,14% 416.400
20/11/2020 62,29 63,68 61,92 63,13 +0,48% 2,83% 395.800
19/11/2020 61,71 63,12 61,56 62,83 +1,78% 2,53% 205.100
18/11/2020 63,00 63,61 61,72 61,73 -1,72% 3,00% 424.300
17/11/2020 61,00 63,00 60,40 62,81 +2,63% 4,26% 477.700
16/11/2020 60,18 61,29 59,34 61,20 +1,83% 3,24% 441.800
13/11/2020 58,88 60,40 58,88 60,10 +1,03% 2,58% 248.800